EUVIMEDEUVIMED entdecken
Crossref

Ruxolitinib: JAK2 inhibitor for treatment of myelofibrosis

Adam Mead

Future Prescriber · 2012

DOI: 10.1002/fps.100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Prescriber, 2012. Verfasst von Adam Mead.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ruxolitinib is an orally administered JAK2 inhibitor for the treatment of disease‐related splenomegaly or symptoms in primary myelofibrosis or myelofibrosis due to polycythaemia vera or essential thrombocythaemia. In our Drug profile Dr Adam Mead presents the clinical data relating to its efficacy and adverse events and comments on its place in therapy. Copyright © 2013 John Wiley & Sons, Ltd.

Zitieren

APA

Mead, A. (2012). Ruxolitinib: JAK2 inhibitor for treatment of myelofibrosis. Future Prescriber. https://doi.org/10.1002/fps.100

Vancouver

Mead A. Ruxolitinib: JAK2 inhibitor for treatment of myelofibrosis. Future Prescriber. 2012. doi:10.1002/fps.100

BibTeX
@article{Mead2012,
  author = {Mead, Adam},
  title = {Ruxolitinib: JAK2 inhibitor for treatment of myelofibrosis},
  journal = {Future Prescriber},
  year = {2012},
  doi = {10.1002/fps.100}
}
Kostenlos starten →